Urovant seeks $150M IPO just a year after launch

Urovant seeks $150M IPO just a year after launch

Source: 
Fierce Biotech
snippet: 

Urovant Sciences came to life in June last year with a focus on urologic disorders and a phase 3 overactive bladder med licensed from Merck. Now, the Roivant subsidiary is eyeing a $150 million IPO, which will push the asset through the clinic in a pair of indications.